journal article·2013-07-23

Smart pH-Sensitive and Temporal-Controlled Polymeric Micelles for Effective Combination Therapy of Doxorubicin and Disulfiram

Xiaopin Duan, Jisheng Xiao, Qi Yin, Zhiwen Zhang, Haijun Yu, Shirui Mao, Yaping Li

ACS Nano· Volume 7· Issue 7
Publisher page

Abstract

The combination of a chemotherapeutic drug with a multidrug resistance (MDR) modulator has emerged as a promising strategy for treating MDR cancer. To ensure two drugs could be simultaneously delivered to tumor region at the optimum ratio, and the MDR modulator could be released earlier and faster than the chemotherapeutic drug to inactivate P-glycoprotein (P-gp) and subsequently inhibit the pumping out of the chemotherapeutic drug, a smart pH-sensitive polymeric micelles system with high drug loading and precise drug ratio was designed and prepared by conjugating doxorubicin (DOX) to poly(styrene-co-maleic anhydride) (SMA) derivative with adipic dihydrazide (ADH) through a acid-cleavable hydrazone bond, and then encapsulating disulfiram (DSF), a P-gp inhibitor as well as an apoptosis inducer, into the micelles formed by the self-assembly of SMA-ADH-DOX (SAD) conjugate. The pH-sensitive polymeric micelles system enabled a temporal release of two drugs: encapsulated DSF was released fast to inhibit the activity of P-gp and restore cell apoptotic signaling pathways, while conjugated DOX was released in a sustained and pH-dependent manner and highly accumulated in drug resistant cells to exert therapeutic effect, due to the inactivation of P-gp by DSF. The smart co-delivery system was very effective in enhancing the cytotoxicity by increasing the intracellular accumulation of DOX and promoting the apoptotic response, and showed the most effective inhibitory effect on the growth of drug-resistant breast cancer xenografts as compared to other combinations of both drugs. In a word, this smart co-delivery system has significant promise for the clinical therapy of MDR cancer.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Drug Transport and Resistance Mechanisms · Nanoparticle-Based Drug Delivery · Dendrimers and Hyperbranched Polymers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China

References (40)

Show source-provided references
1. Woodcock J. · N. Engl. J. Med. · 2011 · 364 · 98510.1056/NEJMp1101548 ↗
2. Jabr-Milane L. S. · Cancer Treat. Rev. · 2008 · 34 · 59210.1016/j.ctrv.2008.04.003 ↗
3. Hu C.-M. J. · Ther. Delivery · 2010 · 1 · 32310.4155/tde.10.13 ↗
4. Lehar J. · Nat. Biotechnol. · 2009 · 27 · 65910.1038/nbt.1549 ↗
5. Hu C.-M. J. · Biochem. Pharmacol. · 2012 · 83 · 110410.1016/j.bcp.2012.01.008 ↗
6. Greco F. · Adv. Drug Delivery Rev. · 2009 · 61 · 120310.1016/j.addr.2009.05.006 ↗
7. Kolishetti N. · Proc. Natl. Acad. Sci. U.S.A. · 2010 · 107 · 1793910.1073/pnas.1011368107 ↗
8. Chen H. · Angew. Chem., Int. Ed. · 2009 · 48 · 929510.1002/anie.200903655 ↗
9. Duan X. P. · Small · 2013 · 9 · 152110.1002/smll.201201390 ↗
10. Kastantin M. · J. Phys. Chem. B · 2010 · 114 · 1263210.1021/jp1001786 ↗
11. Dong H. · ACS Nano · 2012 · 6 · 532010.1021/nn301142r ↗
12. Xiao K. · Biomaterials · 2011 · 32 · 343510.1016/j.biomaterials.2011.01.021 ↗
13. Loo T. W. · Mol. Pharmaceutics · 2004 · 1 · 42610.1021/mp049917l ↗
14. Loo T. W. · J. Natl. Cancer Inst. · 2000 · 92 · 89810.1093/jnci/92.11.898 ↗
15. Regev R. · Biochem. Pharmacol. · 2005 · 70 · 16110.1016/j.bcp.2005.03.032 ↗
16. Krylova O. O. · Chem.—Eur. J. · 2003 · 9 · 393010.1002/chem.200204621 ↗
17. Decorti G. · J. Pharmacol. Exp. Ther. · 1998 · 286 · 525
18. Regev R. · Biochem. Pharmacol. · 1997 · 54 · 115110.1016/S0006-2952(97)00326-2 ↗
19. Hillaireau H. · Cell. Mol. Life Sci. · 2009 · 66 · 287310.1007/s00018-009-0053-z ↗
20. Fernando L. P. · Biomacromolecules · 2010 · 11 · 267510.1021/bm1007103 ↗
21. Nam H. Y. · J. Controlled Release · 2009 · 135 · 25910.1016/j.jconrel.2009.01.018 ↗
22. Wang F. · ACS nano · 2011 · 5 · 367910.1021/nn200007z ↗
23. Pentassuglia L. · Exp. Cell Res. · 2009 · 315 · 130210.1016/j.yexcr.2009.02.001 ↗
24. Chen D. · Cancer Res. · 2006 · 66 · 1042510.1158/0008-5472.CAN-06-2126 ↗
25. Lövborg H. · Int. J. Cancer · 2006 · 118 · 157710.1002/ijc.21534 ↗
26. Yip N. C. · Br. J. Cancer · 2011 · 104 · 156410.1038/bjc.2011.126 ↗
27. Morrison B. W. · Melanoma Res. · 2010 · 20 · 1110.1097/CMR.0b013e328334131d ↗
28. Wang W. · Int. J. Cancer · 2003 · 104 · 50410.1002/ijc.10972 ↗
29. Guo X. · Cancer Lett. · 2010 · 290 · 10410.1016/j.canlet.2009.09.002 ↗
30. Pozza E. D. · Free Radical Biol. Med. · 2011 · 50 · 92610.1016/j.freeradbiomed.2011.01.001 ↗
31. Xu B. · Blood Cells, Mol., Dis. · 2011 · 47 · 26410.1016/j.bcmd.2011.08.004 ↗
32. Reinhardt H. C. · Mol. Cell · 2010 · 40 · 3410.1016/j.molcel.2010.09.018 ↗
33. Huang S. · ACS Nano · 2013 · 7 · 286010.1021/nn400548g ↗
34. Li L. · ACS Nano · 2011 · 5 · 746210.1021/nn202399w ↗
35. Arrowsmith J. · Nat. Rev. Drug Discovery · 2011 · 10 · 32810.1038/nrd3439 ↗
36. Arrowsmith J. · Nat. Rev. Drug Discovery · 2011 · 10 · 8710.1038/nrd3375 ↗
37. Szakacs G. · Nat. Rev. Drug Discovery · 2006 · 5 · 21910.1038/nrd1984 ↗
38. Eckhardt B. L. · Nat. Rev. Drug Discovery · 2012 · 11 · 47910.1038/nrd2372 ↗
39. Adiseshaiah P. P. · Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol. · 2009 · 2 · 99
40. Duan X. P. · Int. J. Nanomed. · 2012 · 7 · 4961